Purification of recombinant hepatitis delta antigen expressed in E. coli cells  by Calogero, R. et al.
Volume 318, number 3, 322-324 FEBS 12198 
0 1993 Federation of European Biochemical Societies 00145793/93/$6.00 
March 1993 
Purification of recombinant hepatitis delta antigen expressed in E. coli 
cells 
R. Calogero”, U. Barbierl ‘b, M. Borlab, S. Osborneb, F. PoissonC and F. Bonellib 
‘Dipartimento di Genetica, Biologia Generale e Molecolare, Universitd di Napoli ‘FedericoH’, 80134 Napoli, Italy, bR&D Diagnostic 
Division, SORIN Biomedica S.p.A., 13040 Saluggia (VC), Italv and ‘Unit& de Virologie, Dkpartement de Microbiologic Mkdicale 
et Molt?ulaire, URA CNRS 1334, CHU Bretonneau, 2 Boulevard TonneIlk, 37044 Tours Cedex, France 
Received 21 January 1993 
Recombinant DNA technology enables the massive production of recombinant hepatitis delta antigen (recHDAg) retaining immunological 
properties and transport functions. However, purification procedures of the recombinant delta antigen have, to date, not been described in the 
literature. We present a purification procedure allowing one to obtain highly purified recHDAg from bacterial cells expressing the hepatitis delta 
antigen. 
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1. INTRODUCTION binant protein from 1 liter of E. cofi cells transformed 
with an expression plasmid harboring recHDAg gene. 
HDV is a human pathogen that was discovered by 
Rizzetto and coworkers in HBV infected patients expe- 
riencing severe liver diseases [ 11. The HDV genome con- 
sists of a circular, single stranded RNA approximately 
1.7 kb in length [2-4] with the ability to fold on itself by 
intramolecular base pairing to form a double stranded 
rod-like structure [5]. The HDV genome and an highly 
basic phosphoprotein, HDAg [6,7], encoded by anti- 
genomic strand of HDV, are packed within an envelope 
composed of HBsAg [8]. HDAg is the only protein en- 
coded by HDV and exists in infected hepatocytes in two 
forms 24 kDa and 27 kDa [8]. Furthermore the larger 
form (214 amino acids) represents a 19 amino acids 
carboxyl-terminal extension of the smaller form (195 
amino acids) [9, lo]. 
2. MATERIALS AND METHODS 
2. I. Materials 
Cultures media, salts, and HPLC solvents were purchased from 
Sigma (USA); HPLC reverse phase columns were purchased from 
Waters (USA) and gel-filtration columns were purchased from Biorad 
(USA). HDAg detection kits and the natural antigen were supplied by 
SORIN Biomedica (I). 
2.2. Methods 
2.2.1. Cloning and expression of recHDAg in E. coli 
The clomng strategy and the expression procedure have been previ- 
ously described [14]. 
2.2.2. BacterIaI paste lysis 
Recombinant DNA technology enables a massive 
production of recombinant delta antigen retaining im- 
munological properties and transport functions [ 1 l-l 51. 
However, purification procedures of the recHDAg 
have, to date, not been described in the literature. 
E coli cells (2 g), strain W3110 (ATCC 27325), transformed with 
pSORIN-Delta [14], was suspended in solution A (7 M CH,CIN1, 
0.1% TFA) (5 ml). The suspension was sonicated (3 x 1 min, 100 W 
burst. 5°C). incubated for 30 min at 60°C and then clarified by centrif- 
ugation (30 min 10,000 x g, 10°C). Cellular debries were reextracted 
with buffer A (5 ml) and the extraction solution clarified by centrifu- 
gation as described above. 
In this paper we present a recHDAg purification pro- 
cedure which allow yields of more than 1 mg of recom- 
2.2.3. Organic precipitation 
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The lysis supernatant and the cellular debries extraction solution 
were pooled and diluited I:1 with solution B (50% CH,CN, 0.2% 
TFA). The solution was incubated at 5°C for 30 min, with stirring, 
and subsequently clarified by centrifugation as described above. An 
aliquot of the clarified solution (0.1 ml) was dried under vacuum, 
dissolved in water (0 1 ml) dialized against buffer C (8 M urea, 50 mM 
sodium acetate. pH 5.5). I ,ul of the dialized solution (1.5 ml) was 
loaded on a 12.5% acrylamide SDS-PAGE gel (Fig. 1, lane A) 
22.4. Reverse phase chromatography 
The clear supernatant. after organic precipitation, was loaded on a 
reverse phase column (19 x 300 mm, C18-Deltapak) equilibrated in 
0.5 x solution B (flow rate = 10 ml/min, detector 215 nm). The un- 
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bound material was washed out with 0.5 x solution B until the baseline 
returned to zero. The adsorbed proteins were eluited with a 30 min 
linear gradient of CH,CN (25% to 50%, flow rate=10 mUmin). The 
peak fraction containing, the higher level of recHDAg immunological 
reactivity (hatched peak, Fig. 2) was dried under vacuum and dis- 
solved in 2% acetic acid solution (1 ml); 1 ~1 was loaded on a 12.5% 
acrylamide SDS-PAGE gel (Fig. 1, lane B). 
2.2.5. Gel-filtration chromatography 
Partially purified recHDAg was loaded onto a silica based gel- 
filtration column (7.8~600 mm, Biosil-250) equilibrated in solution B 
(flow rate=1 ml/min, detector 215 nm) the eluted material was col- 
lected in 0.25 ml fractions. The fractions, corresponding to molecular 
weights 35 to 30 kDa, containing the HDAg immunoreactivity, were 
pooled; 1 ~1 of the immunoreactive pool was loaded on a 12.5% 
acrylamide SDS-PAGE gel (Fig. 1, lane C). 
2.3. Western blot and ELISA unmunoassays 
Western blot analysis was done on purified recHDAg (data not 
shown) using a modified Towbin’s protocol [16]. RecHDAg im- 
munoreactivity detection in column eluates (data not shown) was 
performed using a commercial ELISA sandwich immunoassay for 
detection of HDAg (ETI-DELTA-K). ELISA dilution curve immu- 
noassays (Fig. 3) were performed using a commercial ELISA single 
step immunoinhibition kit (ETI-ABDELTA-K). All the assays were 
performed on recHDAg diluted in anti-HD negative human serum 
and following the procedures recommended by the manifacturer. 
2.4. RNA Binding assays 
The recHDAg RNA binding activity was evaluated with the proce- 
dure described by F. Poisson et al. [17]. RecHDAg was coated on 
NUNC microtiter plates at 12.5 ng/well, 25 ng/well, 50 @well, 100 
@well and 200 @well as described elsewhere [17]. 
3. RESULTS AND DISCUSSION 
We have developed a purification procedure for a 
recHDAg expressed in E. coli. The purified recHDAg 
is a fusion protein consisting of 8 amino acids of the 
NH,-terminus of /I-galactosidase, HDAg sequence 
truncated at aminoacid 204 and a trailer of 49 amino 
acids encoded by tet gene [14]. The antigen is very hy- 
drophilic, is expressed in the cytosol of E. coli [14] and 
represents about 1% of the total E. coli proteins (R. 
Calogero et al., personal comunication). We have used 
harsh conditions for the purification to reduce prote- 
olytic degradation of the recombinant antigen. We puri- 
fied 1 to 2 mg of recHDAg from 1 liter bacterial culture. 
The recHDAg had a purity higher than 95% (found out 
by scanning on a Coomassie stained gels). RecHDAg 
has a molecular weight of 30 kDa (Fig. 1, lane C) and 
is soluble in acidic buffers, forming insoluble aggregates 
at pHs higher than 7 (data not shown). The sequencing 
of the first 20 amino acids at the NH,-terminus con- 
firmed the sequence predicted from the DNA sequenc- 
ing. The recHDAg, from an immunological point of 
view, is more stable than the natural one (Table I). A 
substantial decrease (7%) in the immunoreactivity of the 
natural HDAg as compared to the recombinant antigen 
is observed after 7 days at 37” C. We observed a more 
drastic effect (> 20%) after incubation for 3 days at 
45°C (Table I). 
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Fig. 1. In the SDS page gel recHDAg is indicated by an arrow. Lane 
A: E. co/i clarified lysate after CHpCN addition. Lane MW: Biorad 
prestained low molecular weight markers. Lane B: peak fraction of 
reverse phase chromatography associated with HDAg immunoreac- 
tivity. Lane C: gel-filtration pool of the 30 kDa purified recHDAg. 
The recombinant antigen has shown an immunologi- 
cal behavior similar to the natural one, as demonstrated 
in endpoint immunoinhibition assays, where a sensibil- 
ity identical to the natural HDAg was achieved (Fig. 3). 
The recombinant antigen retained specific HD- 
genome RNA binding activity (Fig. 4). The RNA bind- 
ing to recHDAg was evaluated using digoxigenin la- 
beled RNAs [ 171. The recHDAg bound more efficiently 
HDV RNAs (Fig. 4, open and closed triangles) respect 
to the control RNAs (Fig. 4, open and closed squares). 
Furthermore, the recHDAg bound more efficiently the 
antigenomic strand (Fig. 4, closed triangles) than the 
genomic strand (Fig. 4, open triangles). Those genomic 
and antigenomic strands contain a rod-like structure 
that has been shown to allow HDAg binding [18]. 
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Fig. 2. Elution profile of the reverse phase column (see Methods). 
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Table I 
The retention of immunoreactivity of the natural and recombinant 
antigen was analyzed in accelerated stability studies 
Temperatures 
4°C 37°C 45°C 
(7 days) (7 days) (3 days) 
Residual % immunoreactivity 
Sera HDAg recHDAg HDAg recHDAg HDAg recHDAg 
NC-O 100 100 81.5 98.8 71.2 95.4 
NC-l 100 100 80.4 94.8 69.8 92.0 
NC-2 100 100 84.0 95.7 67.0 93.5 
PS-01 100 100 94.3 85.0 85.7 100.1 
PS-65 100 100 95.0 90.3 75.8 90.5 
PS-66 100 100 82.2 94.7 76.2 100.3 
~~__ 
mean 100 100 86.2 93.2 74.3 96.9 
Each conditton was tested in triplicates on 3 negative sera (NC-O, 
NC-l, NC-2) and 3 positive sera (PS-01, PS-65, PS-66) comparmg 
various batches of recombinant and natural antigen. The recHDAg 
shows greater stability to thermal shock than the natural one. The loss 
of binding capacity for the recHDAg is within - 5% (? 1%) as com- 
pared to - 20% (+ 1%) for the natural HDAg. 
The level of purity and the yield of protein, which we 
have achieved, will allow the use of recHDAg in the 
development of new assays for the in vitro detection of 
HDV infection in human patients. Moreover, substitu- 
tion of recHDAg in test formats would prevent the 
present hazards to workers involved in the purification 
of the natural one from large quantities of HBV/HDV 
infected material. 
Fig. 3. Immunoreactivity of recHDAg as compared to that of the 
natural antigen was evaluated finding out the endpoint titers of two 
anti-HD positive human sera (PS-65, PS-66) representmg moderately 
positive specimens. Each specimen was serially diluted in negative 
human sera and tested in duplicate. The sensitivities found for each 
of the antigen types were essentially identical. 
Fig. 4. The results of the recHDAg RNA binding activity are given 
in absorbance values at 450 nm referring to various recHDAg coating 
concentrations (see Methods). Genomic strand (open triangles) is a 
1220 nucleotides long RNA containing nucleotides 1420 to 1679 and 
nucleotides 1 to 962 of HDV genome. Antigenomic strand (closed 
triangles) contains the sequences complementary to the genomic 
strand. Lambda (open square) is a 1.37 kb RNA generated by tran- 
scription of a lambda fragment inserted m a pGEM plasmid [17]. 
pgem4 (closed square) is a 2.6 kb RNA obtained by transcription of 
the NheI cut pGEM-4 plasmid [17]. BSA and OVA do not bind any 
of the as mentioned above RNAs (data not shown). 
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